Detrimental Effects of Tumor Progression on Cognitive Function of Patients With High-Grade Glioma
- 1 December 2006
- journal article
- neurooncology
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (34), 5427-5433
- https://doi.org/10.1200/jco.2006.08.5605
Abstract
Purpose: There is growing recognition that the primary cause of cognitive deficits in adult patients with primary brain tumors is the tumor itself and more significantly, tumor progression. To assess the cognitive performance of high-grade glioma patients, prospectively collected cognitive performance data were analyzed. Patients and Methods: We studied 1,244 high-grade brain tumor patients entered onto eight consecutive North Central Cancer Treatment Group treatment trials that used radiation and nitrosourea-based chemotherapy. Imaging studies and Folstein Mini-Mental State Examination (MMSE) scores recorded at baseline, 6, 12, 18, and 24 months were analyzed to assess tumor status and cognitive function over time. Results: The proportion of patients without tumor progression who experienced clinically significant cognitive deterioration compared with baseline was stable at 6, 12, 18, and 24 months (18%, 16%, 14%, and 13%, respectively). In patients without radiographic evidence of progression, clinically significant deterioration in MMSE scores was a strong predictor of a more rapid time to tumor progression and death. At evaluations preceding interval radiographic evidence of progression, there was significant deterioration in MMSE scores for patients who were to experience progression, whereas the scores remained stable for the patients who did not have tumor progression. Conclusion: The proportion of high-grade glioma patients with cognitive deterioration over time is stable, most consistent with the constant pressure of tumor progression over time. Although other factors may contribute to cognitive decline, the predominant cause of cognitive decline seems to be subclinical tumor progression that precedes radiographic changes.Keywords
This publication has 36 references indexed in Scilit:
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III TrialJournal of Clinical Oncology, 2004
- A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastasesInternational Journal of Radiation Oncology*Biology*Physics, 2002
- Risk of symptomatic brain tumor recurrence and neurologic deficit after radiosurgery alone in patients with newly diagonised brain metastases: results and implicationsInternational Journal of Radiation Oncology*Biology*Physics, 2002
- Adverse long-term effects of brain radiotherapy in adult low-grade glioma patientsNeurology, 2001
- Postoperative Radiotherapy in the Treatment of Single Metastases to the BrainJama-Journal Of The American Medical Association, 1998
- Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy.Journal of Clinical Oncology, 1994
- Radiation‐induced dementia in patients cured of brain metastasesNeurology, 1989
- Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: A prospective multicenter trial of the scandinavian glioblastoma study groupCancer, 1981
- Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomasJournal of Neurosurgery, 1978